These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 26568191

  • 1. HDL abnormalities in nephrotic syndrome and chronic kidney disease.
    Vaziri ND.
    Nat Rev Nephrol; 2016 Jan; 12(1):37-47. PubMed ID: 26568191
    [Abstract] [Full Text] [Related]

  • 2. Lipotoxicity and impaired high density lipoprotein-mediated reverse cholesterol transport in chronic kidney disease.
    Vaziri ND.
    J Ren Nutr; 2010 Sep; 20(5 Suppl):S35-43. PubMed ID: 20797569
    [Abstract] [Full Text] [Related]

  • 3. Lipid disorders and their relevance to outcomes in chronic kidney disease.
    Vaziri ND, Norris K.
    Blood Purif; 2011 Sep; 31(1-3):189-96. PubMed ID: 21228589
    [Abstract] [Full Text] [Related]

  • 4. Lipid abnormalities in chronic renal failure, nephrotic syndrome and dialysis.
    Kes P.
    Acta Med Croatica; 2001 Sep; 55(4-5):177-86. PubMed ID: 12398021
    [Abstract] [Full Text] [Related]

  • 5. [Lipoprotein disorders in chronic kidney failure, nephrotic syndrome and dialysis].
    Kes P, Reiner Z, Brunetta B.
    Lijec Vjesn; 2002 Sep; 124(11-12):372-7. PubMed ID: 12679979
    [Abstract] [Full Text] [Related]

  • 6. HDL and Kidney Diseases.
    Cao H, Meng X.
    Adv Exp Med Biol; 2022 Sep; 1377():163-170. PubMed ID: 35575929
    [Abstract] [Full Text] [Related]

  • 7. Nephrotic syndrome causes upregulation of HDL endocytic receptor and PDZK-1-dependent downregulation of HDL docking receptor.
    Vaziri ND, Gollapudi P, Han S, Farahmand G, Yuan J, Rahimi A, Moradi H.
    Nephrol Dial Transplant; 2011 Oct; 26(10):3118-23. PubMed ID: 21459782
    [Abstract] [Full Text] [Related]

  • 8. Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease.
    Moradi H, Pahl MV, Elahimehr R, Vaziri ND.
    Transl Res; 2009 Feb; 153(2):77-85. PubMed ID: 19138652
    [Abstract] [Full Text] [Related]

  • 9. Characteristics of lipid metabolism under different urinary protein excretion in children with primary nephrotic syndrome.
    Hu P, Lu L, Hu B, Du PF.
    Scand J Clin Lab Invest; 2009 Feb; 69(6):680-6. PubMed ID: 19468931
    [Abstract] [Full Text] [Related]

  • 10. [Alterations of fat metabolism in renal disease - pathogenetic mechanisms (author's transl)].
    Hörl WH, Hörl M, Heidland A.
    Klin Wochenschr; 1982 Apr 01; 60(7):327-36. PubMed ID: 6122754
    [Abstract] [Full Text] [Related]

  • 11. Lipid abnormalities and oxidized LDL in chronic kidney disease patients on hemodialysis and peritoneal dialysis.
    Samouilidou EC, Karpouza AP, Kostopoulos V, Bakirtzi T, Pantelias K, Petras D, Tzanatou-Exarchou H, J Grapsa E.
    Ren Fail; 2012 Apr 01; 34(2):160-4. PubMed ID: 22172020
    [Abstract] [Full Text] [Related]

  • 12. Statins and renal diseases: from primary prevention to renal replacement therapy.
    D'Amico G.
    J Am Soc Nephrol; 2006 Apr 01; 17(4 Suppl 2):S148-52. PubMed ID: 16565241
    [Abstract] [Full Text] [Related]

  • 13. Is the aggressive management of hyperlipidemia in nephrotic syndrome mandatory?
    Keane WF, St Peter JV, Kasiske BL.
    Kidney Int Suppl; 1992 Oct 01; 38():S134-41. PubMed ID: 1405364
    [Abstract] [Full Text] [Related]

  • 14. [Lipid disturbances in the nephrotic syndrome].
    Chmielewski M, Zdrojewski Z, Rutkowski B.
    Przegl Lek; 2003 Oct 01; 60(11):758-61. PubMed ID: 15058052
    [Abstract] [Full Text] [Related]

  • 15. Acyl-coenzyme A:cholesterol acyltransferase inhibition ameliorates proteinuria, hyperlipidemia, lecithin-cholesterol acyltransferase, SRB-1, and low-denisty lipoprotein receptor deficiencies in nephrotic syndrome.
    Vaziri ND, Liang KH.
    Circulation; 2004 Jul 27; 110(4):419-25. PubMed ID: 15262831
    [Abstract] [Full Text] [Related]

  • 16. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA, Stephens BW.
    Adv Chronic Kidney Dis; 2011 Mar 27; 18(2):120-31. PubMed ID: 21406297
    [Abstract] [Full Text] [Related]

  • 17. Lipids and progressive kidney disease.
    Moorhead JF.
    Kidney Int Suppl; 1991 Apr 27; 31():S35-40. PubMed ID: 2046269
    [Abstract] [Full Text] [Related]

  • 18. Plasma Nitration of High-Density and Low-Density Lipoproteins in Chronic Kidney Disease Patients Receiving Kidney Transplants.
    Bakillah A, Tedla F, Ayoub I, John D, Norin AJ, Hussain MM, Brown C.
    Mediators Inflamm; 2015 Apr 27; 2015():352356. PubMed ID: 26648662
    [Abstract] [Full Text] [Related]

  • 19. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome.
    Joven J, Villabona C, Vilella E, Masana L, Albertí R, Vallés M.
    N Engl J Med; 1990 Aug 30; 323(9):579-84. PubMed ID: 2381443
    [Abstract] [Full Text] [Related]

  • 20. Dietary cholesterol induced changes in lipid profile in patients with nephrotic syndrome and chronic renal failure.
    Jain PK, Arora RC, Agarwal N, Garg RK, Arora S, Gurbaxani RK, Sharma D.
    J Assoc Physicians India; 1991 Oct 30; 39(10):751-3. PubMed ID: 1816199
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.